Board

Lars Rebien Sørensen has been a member of the Novo Nordisk Foundation’s Board of Directors since 2017. As Chair, Lars Rebien Sørensen is elected for one year at a time. He was last elected in Spring 2025. He is considered a non-independent member due to his position as Chair on the Board of Novo Nordisk A/S.

Lars was born in 1954 and holds an MSc in Forestry from the Copenhagen Royal Veterinary and Agricultural University as well as a BSc in International Economics from Copenhagen Business School.

Lars Rebien Sørensen serves as Chair of the Board of Novo Nordisk A/S, Vice Chair of the Board of Ferring Pharmaceuticals (Switzerland) and Member of the Board of Jungbunzlauer Suisse AG (Switzerland).

Lars is an Adjunct Professor at the University of Copenhagen’s School of Life Sciences and Adjunct Professor at Center for Corporate Governance at Copenhagen Business School.

Board competencies
Lars Rebien Sørensen has corporate leadership experience from a major international company, deep insight into the businesses and practices of the companies in the Novo Group as well as knowledge of the international pharmaceutical industry. He has broad experience with board work.

Lars Rebien Sørensen is considered a non-independent member due to his position as Chair on the Board of Novo Nordisk A/S.

Lars Henrik Munch serves as Chair of the Board of The Politiken-Foundation and A/S Politiken Holding and as Chair of the Boards of the Louisiana Museum of Modern Art, Museumsfonden, Louisiana Fonden, BRFfonden, BRFholding A/S, BRFinvest a/s, BRFejendomme A/S, and Fonden for Håndværkskollegier.

Furthermore, Lars Henrik Munch is a member of the boards of Utzon Center A/S and the KUNSTEN Museum of Modern Art, Aalborg. Lars Henrik Munch is also a member of the World Association of News Publishers (Paris), as well as Chair of the Advisory Board for Master of Management Development, Copenhagen Business School (CBS) and Vice Chair of the Board of Erhvervslivets Tænketank. Lars Henrik Munch serves as Adjunct Professor at the Department of Organisation, CBS.

Board competencies: Experience with society and social conditions, art and culture, media and board work.

Lars Henrik Munch is considered an independent board member

Christopher A. Voigt is the Daniel I.C. Wang Professor of Advanced Biotechnology and Department Head in Biological Engineering at Massachusetts Institute of Technology (MIT), as well as the co-director of the Synthetic Biology Center at MIT.

Christopher A. Voigt is a founding member of the U.S. National Science Foundation-funded Engineering Biology Research Center, former founding Editorin-Chief of the ACS Synthetic Biology journal, and co-founder of the companies Asimov (therapeutics bio-manufacturing) and Pivot Biotechnologies (agriculture).

Board competencies: Extensive scientific advisory experience. Expert knowledge within synthetic biology and genetic engineering as well as the translation of cutting-edge science into innovations and start-up companies.

Christopher A. Voigt is considered an independent board member.

Employee-elected board member, Environmental Specialist, Novonesis A/S.
Member of the board of the Novo Nordisk Foundation since March 2022.

Last elected in May 2026 for a four-year term.

Nana Bule Sejbæk serves as Chair of the National Digital Council and Energy Crisis Staff, and as Chair of the Board of Carbfix. Furthermore, Nana Bule Sejbæk is a member of the boards of Arla Foods and Energinet, and works as an Operating Advisor with Goldman Sachs Asset Management.

Board competencies: Senior Executive experience from a large international Tech company with a proven track record of driving transformation and delivering business growth. Board word experience.

Nana Bule is considered an independent board member

Lars Green was born in 1967 and holds a MSc (Business Administration).

Lars Green serves as Chair of the Board of Directors of Novo Holdings A/S, and serves on the Board of Trustees of the LEO Foundation, the Board of Directors of LEO Pharma A/S, H. Lundbeck A/S and Pharmacosmos A/S. Furthermore, Lars Green serves as Vice Chair of the Danish Committee on Corporate Governance.

Lars Green brings more than 30 years of experience from the health care and life science industries. He joined Novo Nordisk A/S in 1992 and held various financial leadership positions incl. regional CFO roles in Japan and North America as well as Group Finance before joining Executive Management in 2017 as EVP of Business Services. In 2019, Lars Green joined Novozymes A/S where he served as CFO until end 2023.

Lars Green is considered a non-independent board member due to his recent position in Novozymes A/S (Novonesis).

Barbara Casadei was born in 1959 and graduated in Medicine at the University of Pavia, Italy and moved to the University of Oxford, UK in 1989 where she was awarded a DPhil in 1995 and a Professorship in Cardiovascular Medicine in 2006. She is currently British Heart Foundation Professor of Cardiovascular Medicine, Honorary Consultant Cardiologist, and Head of the National Heart and Lung Institute at Imperial College London.

Barbara is Fellow of the UK Academy of Medical Sciences, holds the highest honour of the British Cardio-vascular Society (The Mackenzie Medal) and of the European Society of Cardiology (Gold Medal), and is Past President of the European Society of Cardiology (2018-20). She is the founder of EuroHeart, an initiative supporting the assessment and improvement of quality of cardiovascular care in Europe and a member/chair of several Scientific Advisory Boards, including the Leducq Foundation, the Netherland Heart Institute and the Max Delbrück Centre for Molecular Medicine in Berlin. She was the Roman W. DeSanctis Visiting Professor, Harvard Medical School, in 2021; The Keith Reimer Distinguished Lecturer of the Inter-national Society for Heart Research in 2022; the Lucian Prize awardee, Canada in 2023; and the Paul Dud-ley White International Lecturer of the American Heart Association in 2024.

Barbara Casadei is considered an independent board member.

Employee-elected board member, Scientific Director, Novo Nordisk A/S.
Member of the board of the Novo Nordisk Foundation since May 2026.

Last elected in May 2026 for a four-year term.

Employee-elected board member, Operator, Novo Nordisk A/S.
Member of the board of the Novo Nordisk Foundation since May 2026.

Last elected in May 2026 for a four-year term.

Employee-elected board member, Senior Finance Partner, Novo Nordisk Foundation.
Member of the board of the Novo Nordisk Foundation since May 2026.

Last elected in May 2026 for a four-year term.

Responsibilities
As Chief Legal Officer of Legal & Governance, Pelle is responsible for the Novo Nordisk Foundation’s governance and legal affairs including intellectual property, risk, ethics and compliance. Furthermore, Pelle is appointed as Board Secretary to the Foundation and Novo Holdings A/S and is also a member of the Foundation’s Executive Management.

Other positions and management duties
Pelle serves as the Foundation’s representative on the boards of the Foundation’s subsidiary companies: Danish Centre for AI Innovation A/S; Quantum Foundry P/S; NIVI Development P/S; Cellerator P/S and QuNorth A/S.

Background
Pelle began his career as an attorney at Denmark’s leading law firm Kromann Reumert, where he specialised in corporate law, mergers and acquisitions, intellectual properties and regulatory matters. He has also worked as Deputy General Counsel at the global jewellery manufacturer Pandora, and prior to joining the Foundation, Pelle was Senior Vice President and Group General Counsel at Demant, where he led a team of 50 legal professionals worldwide. Pelle is listed on the Legal 500 GC Powerlist, Denmark.

Education

• 2007: Authorisation as attorney-at-law, Danish Bar & Law Society
• 2004: Master of Law, University of Copenhagen

Pelle joined the Novo Nordisk Foundation in June 2023.

Contact
Susan Nielsen, Executive PA
[email protected]
+45 5354 5607